Therapeutic Research

Abstract

Background: Once‒weekly glucagon‒like peptide 1 receptor agonist semaglutide has been available in Japan since June 2020. However, there is only a few report the long‒term efficacy and safety of once‒weekly semaglutide in Japan. 　　Object: We evaluated the long‒term efficacy and safety of once‒weekly semaglutide in Japan. 　　Method: We investigated the changes of HbA1c and body weight at 1 year, 1.5 years, 2 years after treatment on semaglutide in145 type 2 diabetes patients. 　　Results: HbA1c and body weight were significantly decreased at 1, 1.5, and 2 years after treatment on Semaglutide. 　　Conclusion: We demonstrated the long‒term efficacy and safety of once‒weekly semaglutide. However, the limitation of this study is that it is retrospective and the data is limited to a single institution, and large‒scale data collection and analysis at multiple institutions is desired in the future.